After patient death, FDA lifts hold on 1 of 2 late-stage trials testing Intellia’s CRISPR therapy
After patient death, FDA lifts hold on 1 of 2 late-stage trials testing Intellia’s CRISPR therapy
Body unavailable. Use the original source.
After patient death, FDA lifts hold on 1 of 2 late-stage trials testing Intellia’s CRISPR therapy
A compact weekly email covering company moves, product signals, regulatory updates, and notable funding.